Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Alectos Therapeutics Inc.
DescriptionO-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitor
Molecular Target O-linked N-acetylglucosaminidase (O-GlcNAcase)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationProgressive supranuclear palsy (PSP)
Indication DetailsTreat progressive supranuclear palsy (PSP)
Regulatory Designation U.S. - Orphan Drug (Treat progressive supranuclear palsy (PSP))
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today